产品活性： Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...

台康生技(6589)今(10)日公告乳癌生物相似药EG12014(Trastuzumab Biosimilar, also called EGI2014)FDA药证申覆未通过，查厂结果充填厂仍需改善。台康生技今日股价开盘直接锁在跌停板82.9元，至10:40，超过2800张的卖 ...

The Toxicities and Adverse Effects That Emergency Physicians Must Know,” published in the December 2024 issue of Emeregency ...

A University of Liverpool study reveals how two critical molecules present in 'HER2-positive' breast cancer - one of the most ...

The efficacy of trastuzumab deruxtecan after endocrine-based therapy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 is unknown.

A significant breakthrough in breast cancer research has uncovered a key mechanism driving cancer invasion and drug ...

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

A significant advance in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A ...

The government's drug funding agency Pharmac is asking for public feedback on its proposal to fund four new medicines for ...

A significant breakthrough in breast cancer research has uncovered a key mechanism driving cancer invasion and drug ...

One in nine New Zealand women get breast cancer in their lifetimes, and around 16% of metastatic breast cancers are ...